Ipsen Announces Positive Results From Phase IIa Clinical Study Of Dysport® In The Treatment Of Patients With …
PARIS–(BUSINESS WIRE)–Regulatory News: Ipsen (Paris:IPN) (Euronext: IPN; ADR: IPSEY) today announced positive results from its phase IIa clinical trial assessing Dysport® in the treatment of Neurogenic Detrusor Overactivity (NDO) in patients with urinary incontinence not adequately managed by anticholinergics. Results show that treatment with Dysport® was associated with a mean reduction from … Read News
Should You Buy Actavis?
Dublin, Ireland-based Actavis Plc (ACT) is a pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic and brand pharmaceutical products. … Read News